Samra Turajlić, Director at CRUK Manchester Institute, shared a post on LinkedIn:
“I am delighted with the progress we have made in MANIFEST IO over the past two years. Yesterday I presented our work-in-progress at the at the Festival of Genomics in London and was struck by the level of engagement and enthusiasm from both academic and industry colleagues. Next month, we will also be launching our prospective recruitment of 3,000 patients receiving immuno-oncology therapies.
One of the key lessons from this period has been how much further we need to go to translate rich human immune data into therapeutic insight — and, at the same time, how much potential there is to learn across traditionally separated disease areas. In particular, we are increasingly recognising the profound overlap between cancer immunology, inflammation, and autoimmunity: shared mechanisms, common multi-omic technologies, and an accelerating convergence of therapeutic strategies.
We are grateful for the support and trust of our many industry and biotech partners.”
More posts featuring Samra Turajlić.